Decitabine/cedazuridine plus venetoclax met its primary endpoint with a complete response rate of 46.5%. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...
PLEASANTON, Calif.-- (BUSINESS WIRE)--Astex Pharmaceuticals, Inc. announces today top-line results from the ASCERTAIN phase 3 study evaluating oral decitabine and cedazuridine fixed-dose combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback